Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC57H62F2N10O10S2 |
InChIKeyUNADZUGJDDCVKE-RVLLIKLQSA-N |
CAS Registry2417370-67-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 17 Feb 2021 |